Enclomiphene mechanism of action: how it raises testosterone

Last updated 2026-07-27

What is enclomiphene, exactly?

Enclomiphene citrate is one half of a molecule most people have already heard of: clomiphene citrate (brand name Clomid). Clomiphene isn't a single compound. It's a mixture of two geometric isomers, enclomiphene (the trans-isomer, roughly 62% of the mixture) and zuclomiphene (the cis-isomer, roughly 38%) ^[1]. These two isomers behave differently in the body. Enclomiphene is the one doing most of the useful work in men: it's a shorter-acting estrogen receptor antagonist at the hypothalamus. Zuclomiphene is longer-acting, weakly estrogenic in some tissues, and is largely considered the isomer responsible for side effects like mood changes and visual disturbances that show up in clomiphene users ^[2]. So when a compounding pharmacy sends you "enclomiphene," you're getting the isolated trans-isomer, not the full clomiphene mixture. That distinction matters both for how it works and for what side effects to expect. It is not the same drug as generic Clomid, even though they're chemically related and often confused in forum discussions.

How does enclomiphene raise testosterone? (the actual mechanism)

Enclomiphene is a selective estrogen receptor modulator (SERM). In men, its main job happens in the hypothalamus, where it blocks estrogen from binding to estrogen receptors on the neurons that control gonadotropin-releasing hormone (GnRH) ^[3]. Here's the loop it interrupts. Normally, testosterone gets aromatized into estradiol, and that estradiol feeds back to the hypothalamus and pituitary to say "enough testosterone, dial it back." This is a negative feedback loop, same basic wiring as a thermostat. Enclomiphene sits on the estrogen receptor and blocks that signal from getting through. The hypothalamus reads the blocked signal as "estrogen and testosterone must be low," even though they aren't, and responds by increasing GnRH pulses. More GnRH drives the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH is what tells the testicular Leydig cells to produce testosterone. FSH acts on Sertoli cells to support spermatogenesis. Because enclomiphene works upstream of the testicle, both of these downstream effects happen together: testosterone goes up, and the testicles keep making sperm, because they're still getting the signal to do so. A 2013 mechanistic review put it plainly: enclomiphene "increases endogenous testosterone production by blocking the negative feedback of estrogen at the hypothalamus," which distinguishes its effect from exogenous testosterone replacement that suppresses the same axis ^[3]. This is genuinely the whole story in terms of mechanism, it's just one lever, pulled at the top of the hormonal chain rather than by replacing the end product.

Why does TRT shut down fertility but enclomiphene doesn't?

This is the question almost everyone researching enclomiphene actually wants answered, so it's worth being precise about it. Exogenous testosterone (injections, gels, pellets) enters the bloodstream directly. The hypothalamus and pituitary sense that testosterone (and the estradiol made from it) is already high, so they shut down GnRH and LH/FSH output. Without LH, the Leydig cells stop producing testosterone on their own. Without FSH, Sertoli cell support for sperm production drops. Testicles that aren't getting signaled tend to shrink, and sperm counts fall, sometimes to zero. This is well documented: a 1996 WHO multicenter contraceptive trial using weekly testosterone enanthate injections induced azoospermia (zero sperm count) in 65 to 90% of men depending on ethnicity, precisely because it's suppressing the same axis enclomiphene is stimulating ^[4]. Enclomiphene does the opposite at the top of the loop. It doesn't add testosterone from outside. It blocks the brain from seeing the estrogen signal, so LH and FSH stay up or increase, and the testicles keep receiving the "produce" signal. That's why testicular size and sperm production tend to be preserved on enclomiphene in ways they are not on TRT. The honest caveat: "tends to preserve" is not the same as "guarantees." Long-term, controlled fertility outcome data (actual pregnancy rates, sperm counts before and after months of use) are still thin. Most of the enclomiphene evidence base measures LH, FSH, and testosterone as surrogate markers, not live birth rates. If you're actively trying to conceive, this is a conversation for a reproductive urologist, not something to assume from a mechanism alone.

What does the clinical trial evidence actually show?

The most cited human data on enclomiphene comes from a set of Phase 2 and Phase 3 trials run under the name Androxal, sponsored by Repros Therapeutics, studying men with secondary hypogonadism (low testosterone with low or inappropriately normal LH/FSH) and obesity. A Phase 2 trial published in the Journal of Sexual Medicine (2013) compared enclomiphene to topical testosterone gel in hypogonadal men. Enclomiphene raised testosterone into the normal range while preserving sperm counts and elevated LH/FSH; the testosterone gel group saw suppressed LH/FSH and a drop in sperm concentration ^[5]. That head-to-head contrast is the core data point behind the entire fertility-preservation argument for enclomiphene. Repros Therapeutics pursued FDA approval for Androxal (enclomiphene citrate) through the mid-2010s. It never reached the market. The FDA issued Complete Response Letters citing insufficient data on efficacy and cardiovascular safety, and Repros ultimately discontinued the program ^[6]. As of 2025, there is no FDA-approved enclomiphene product sold under any brand name in the United States. That's a meaningful regulatory fact, not a technicality. It means every dose of enclomiphene sold in the U.S. today is compounded, made by a licensed pharmacy under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, not manufactured and approved as a standalone drug the way, say, testosterone cypionate is ^[7]. Compounded drugs are not FDA-reviewed for safety and efficacy in the same way; they're prepared based on a prescription for an individual patient (503A) or by an outsourcing facility under separate quality standards (503B). If you're weighing enclomiphene against testosterone therapy, you should know you're comparing an approved drug to a compounded one.

How is enclomiphene different from clomiphene (Clomid)?

Clomiphene citrate is FDA-approved, but only for female infertility (ovulation induction), under the brand name Clomid, originally approved by the FDA in 1967 ^[8]. Its use in men for low testosterone or fertility is off-label. Because clomiphene contains both enclomiphene and zuclomiphene, men taking it get the trans-isomer's beneficial hypothalamic antagonism plus the cis-isomer's longer half-life and weaker, more mixed estrogenic activity. Zuclomiphene has a half-life estimated at roughly 30 days versus roughly 4 to 8 days for enclomiphene, and it accumulates with repeated dosing ^[2]. That accumulation is thought to be part of why some men on clomiphene report more mood-related side effects and visual disturbances over time. Enclomiphene, as the isolated isomer, is marketed on the premise of getting the LH/FSH-driving effect without carrying along the isomer researchers link to more side effects. That said, isolating enclomiphene doesn't mean zero side effects. It means a different, generally more favorable side effect profile, based on the mechanistic data available, not zero risk. | Feature | Enclomiphene | Clomiphene (Clomid) | Testosterone (TRT) |

What happens to LH, FSH, and estradiol on enclomiphene?

In practical terms, expect three hormone panels to move together on enclomiphene: total and free testosterone go up, LH and FSH go up (because the drug is stimulating them, not suppressing them), and estradiol typically rises somewhat too, since more testosterone means more substrate for aromatization. This is actually a useful diagnostic signature. If someone's bloodwork shows testosterone up alongside LH and FSH up, that's consistent with enclomiphene doing what it's supposed to do at the hypothalamus. If testosterone is up but LH and FSH are flat or falling, something else is going on, or the person is also using exogenous testosterone. The Phase 2 data from the Journal of Sexual Medicine trial specifically noted this pattern: enclomiphene-treated men maintained LH and FSH within or above baseline, while testosterone-gel-treated men saw suppressed gonadotropins as expected for exogenous replacement ^[5]. That's the number to ask your prescriber for if you want to confirm the drug is working the way the mechanism predicts, rather than just checking testosterone alone.

Does enclomiphene affect testicular size?

Testicular volume is largely maintained by ongoing LH stimulation of the Leydig cells and FSH stimulation of the Sertoli cells, both of which enclomiphene tends to preserve or increase, unlike exogenous testosterone which removes that stimulation. This is the mechanistic basis for why men switching from TRT to enclomiphene sometimes report testicular size recovering. That said, most of the direct data on testicular volume specifically (more than LH/FSH as proxies) comes from small trials and isn't as extensively published as the hormone data. If testicular size and long-term fertility are the actual goal, that's worth raising directly with a urologist alongside routine semen analysis, rather than assuming a hormone panel alone confirms it.

How fast does enclomiphene start working, and how long does it take to see effects?

Because enclomiphene has a shorter half-life than zuclomiphene, roughly in the range of several days rather than weeks, its effects on LH and FSH tend to show up relatively quickly, often within the first 1 to 2 weeks of consistent dosing, with testosterone following as LH stimulates the testes ^[2][3]. Most published trials measured hormone changes at 3-month intervals, so it's hard to give a precise week-by-week curve from the available data. In practice, a follow-up bloodwork check around 4 to 6 weeks after starting is a reasonable window to see whether testosterone and LH/FSH are trending the way the mechanism predicts. If you're mapping out a starting plan, the Enclomiphene Direct dosage guide and the dosage calculator walk through typical starting ranges and how they map to bloodwork timing.

What are the known side effects, and are they different from clomiphene's?

Because enclomiphene lacks the longer-acting zuclomiphene isomer, the side effect profile reported in early trials leans toward things tied to estrogen receptor blockade generally: mood changes, headache, and in some men, visual disturbances, though these were reported less frequently than with clomiphene in the available comparative data ^[2][5]. Estradiol can rise as testosterone rises, which is worth tracking on bloodwork rather than guessing about. Because it isn't FDA-approved as a standalone drug, there is no FDA-approved label with a formally established adverse event profile the way there is for testosterone products. The side effect data available comes from the Repros Phase 2/3 trial program and smaller academic studies, not decades of post-marketing surveillance. That's a real gap, and it's part of why this remains a conversation to have with a prescriber who checks bloodwork rather than something to self-manage from forum posts.

Is compounded enclomiphene legal, and what does 'compounded' actually mean here?

Yes, compounded enclomiphene is legal to prescribe and dispense in the U.S., under the same framework that allows pharmacies to compound many drugs not otherwise commercially manufactured, but it's legal because of that pharmacy compounding framework, not because enclomiphene itself has FDA marketing approval. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound a drug for an identified individual patient based on a valid prescription. Section 503B allows larger "outsourcing facilities" to compound at scale under separate current good manufacturing practice (cGMP) oversight, without requiring a patient-specific prescription before compounding ^[7]. The FDA's own guidance is direct about the limits here: compounded drugs "are not FDA-approved," meaning the agency does not verify their safety, effectiveness, or manufacturing quality the way it does for approved drugs . In practice, this is why the sourcing question matters as much as the mechanism question. A 503B outsourcing facility is a meaningfully different quality bar than an unregulated overseas seller shipping research chemicals with no prescription and no pharmacy oversight. If you're pursuing this route, working with a provider who reviews your labs and prescribes through a legitimate pharmacy is the difference between a controlled compounding process and a genuine gray-market gamble.

How does enclomiphene compare to hCG or clomiphene for preserving fertility?

All three (enclomiphene, clomiphene, and hCG) work by different mechanisms to keep the testicular axis active, and none of them has been rigorously proven in large trials to guarantee fertility preservation or restoration; the comparative evidence is mostly small trials and mechanistic reasoning, not head-to-head outcome studies. hCG mimics LH directly, stimulating the Leydig cells to produce testosterone without going through the hypothalamus at all. That makes it useful for men who need testicular stimulation but whose hypothalamic-pituitary signaling is already impaired for other reasons. Clomiphene and enclomiphene both work upstream, at the estrogen receptor level, with enclomiphene being the isolated, shorter-acting isomer. For men on TRT specifically who want to maintain fertility rather than restart it later, some protocols combine low-dose hCG with testosterone. Enclomiphene is generally discussed as an alternative to TRT altogether (raising your own testosterone rather than replacing it), not typically as an add-on during TRT itself, since adding it while already suppressed with exogenous testosterone doesn't address the underlying suppression. This is a genuinely individualized decision that depends on labs, symptoms, and reproductive goals, and it's one where self-directed dosing off internet protocols is a bad idea.

What should someone starting enclomiphene actually expect, practically?

Baseline labs first: total and free testosterone, LH, FSH, and estradiol, ideally drawn in the morning when testosterone is highest. Repeat labs somewhere in the 4 to 6 week range after starting is a reasonable checkpoint to confirm the LH/FSH/testosterone pattern described above is showing up. Dosing in the compounded market varies by pharmacy and prescriber, typically in the range of 12.5 mg to 25 mg per day or every other day, though this is not standardized the way an FDA-approved label would be, since no such label exists. The Enclomiphene Direct dosage page and cycle length guide cover how these ranges get set and adjusted in practice, and the reconstitution guide is relevant if your pharmacy dispenses it in a form that needs mixing rather than as a ready-made capsule. For men who source it as an injectable rather than oral capsule, which is less common but does happen depending on the compounding pharmacy, the injection sites and how to inject guides cover technique. Enclomiphene Direct's provider-reviewed model connects patients with a prescriber who orders labs and adjusts dosing based on results, then fulfills through a partner pharmacy, rather than shipping product with no clinical oversight attached.

What's the honest bottom line on the evidence?

The mechanism is well established: enclomiphene blocks hypothalamic estrogen receptors, raises LH and FSH, and drives up endogenous testosterone, and this is supported by pharmacology reviews and Phase 2 trial data going back over a decade ^[3][5]. The fertility-preservation angle, relative to TRT, is mechanistically sound and supported by the LH/FSH/sperm-count contrasts seen in the Androxal trial data ^[5]. What's thinner is long-term outcome data: no large, FDA-reviewed trial program ever reached approval, the drug is compounded rather than manufactured under an approved label, and post-marketing safety surveillance in the formal FDA sense doesn't exist for it ^[6]. That doesn't mean it doesn't work; it means the evidence stops well short of the certainty an approved drug label would represent. Anyone considering it should treat it as what it is: a mechanistically well-understood, pharmacy-compounded therapy with promising but incomplete human trial data, best used under a prescriber who's actually tracking your bloodwork rather than guessing.

Frequently asked questions

Is enclomiphene the same thing as clomiphene or Clomid?

No. Clomiphene (Clomid) is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is the isolated trans-isomer, sold separately. Clomiphene is FDA-approved, but only for female infertility, and used off-label in men. Enclomiphene has no FDA approval at all and is sold only as a compounded product ^[1][8].

Is enclomiphene FDA-approved?

No. Repros Therapeutics developed enclomiphene under the name Androxal and sought FDA approval through the mid-2010s, but the FDA issued Complete Response Letters citing insufficient efficacy and cardiovascular safety data, and the program was discontinued. Every enclomiphene product sold today in the U.S. is compounded by a pharmacy, not an FDA-approved manufactured drug ^[6].

How does enclomiphene raise testosterone without injections?

It blocks estrogen receptors in the hypothalamus, which prevents estrogen from signaling "testosterone is high enough." The brain responds by increasing GnRH, which raises LH and FSH from the pituitary, and LH stimulates the testicles to produce more testosterone on their own ^[3].

Does enclomiphene preserve fertility better than TRT?

Mechanistically, yes, it tends to preserve or increase LH and FSH (which support sperm production) rather than suppressing them the way exogenous testosterone does. A Phase 2 trial found enclomiphene preserved sperm parameters while testosterone gel suppressed them, but this isn't the same as proven pregnancy-rate outcomes; long-term fertility outcome data remains limited ^[4][5].

Can enclomiphene cause testicular shrinkage like TRT does?

It's not expected to, based on mechanism, because it keeps LH and FSH signaling active rather than shutting it down. TRT-related testicular shrinkage happens because exogenous testosterone suppresses LH/FSH. Enclomiphene stimulates the same pathway rather than replacing it, so testicular volume is generally expected to be maintained.

What happens to estradiol on enclomiphene?

Estradiol typically rises somewhat as testosterone rises, since testosterone is the substrate for aromatization into estradiol. This is expected and part of why bloodwork monitoring, more than symptom tracking, matters while on enclomiphene.

How long does it take for enclomiphene to raise testosterone?

LH and FSH changes can begin within 1 to 2 weeks given enclomiphene's shorter half-life, with testosterone following as the testicles respond to increased LH. Most trials measured outcomes at 3-month intervals, so a common practical approach is bloodwork around 4 to 6 weeks after starting to check the trend.

Is compounded enclomiphene legal to buy?

Yes, when prescribed by a licensed provider and dispensed by a licensed compounding pharmacy under FDA's 503A or 503B framework. It's legal under pharmacy compounding rules, not because enclomiphene has its own FDA marketing approval, which it does not have ^[7][9].

What's the difference between enclomiphene and hCG for fertility preservation?

hCG mimics LH directly at the testicle, bypassing the hypothalamus. Enclomiphene works higher up, at the estrogen receptor in the hypothalamus, to increase the body's own LH and FSH output. Both aim to keep testicular signaling active, but through different points in the pathway, and neither has large-scale outcome trials proving fertility restoration.

Does enclomiphene have the same side effects as clomiphene?

Early data suggests fewer mood and visual side effects with enclomiphene compared to clomiphene, likely because it lacks the longer-acting zuclomiphene isomer thought to drive those effects. But since enclomiphene isn't FDA-approved, there's no large post-marketing safety database confirming this at scale ^[2][5].

Can women take enclomiphene?

Enclomiphene is studied and marketed for men with low testosterone. Clomiphene, the full isomer mixture, is the FDA-approved drug for female ovulation induction. The isolated enclomiphene product discussed here isn't the approved pathway for female infertility treatment ^[8].

Why isn't there an FDA-approved enclomiphene product on the market?

Repros Therapeutics pursued approval under the name Androxal but received Complete Response Letters from the FDA over insufficient efficacy and cardiovascular safety data in its trial program, and ultimately discontinued development. No sponsor has since brought a standalone enclomiphene product through FDA approval ^[6].

Sources

1. PubChem, National Library of Medicine: Enclomiphene compound summary: Enclomiphene is the trans-isomer of clomiphene citrate, roughly 62% of the mixture, with zuclomiphene the cis-isomer at roughly 38%
2. Kim et al., 'Enclomiphene for the treatment of secondary hypogonadism,' Sexual Medicine Reviews: Zuclomiphene has a much longer half-life than enclomiphene and accumulates with repeated dosing, linked to more mood and visual side effects
3. Kim, Fontanarosa, Pastuszak, 'Enclomiphene citrate for the treatment of secondary male hypogonadism,' Translational Andrology and Urology / mechanistic review: Enclomiphene increases endogenous testosterone by blocking estrogen negative feedback at the hypothalamus, raising GnRH, LH, and FSH
4. World Health Organization Task Force, 'Contraceptive efficacy of testosterone-induced azoospermia,' Fertility and Sterility, 1996: Weekly testosterone enanthate injections induced azoospermia in 65 to 90 percent of men depending on ethnicity in a multicenter WHO trial
5. Kim et al., Phase 2 trial, 'Randomized clinical trial of enclomiphene versus testosterone gel,' Journal of Sexual Medicine, 2013: Enclomiphene raised testosterone while maintaining LH, FSH and sperm parameters; testosterone gel suppressed gonadotropins and sperm concentration
6. U.S. Food and Drug Administration, Complete Response Letter history for Androxal (enclomiphene citrate), Repros Therapeutics disclosures: Enclomiphene (Androxal) never received FDA approval; Repros Therapeutics received Complete Response Letters citing insufficient efficacy and cardiovascular safety data
7. U.S. Food and Drug Administration, Clomid (clomiphene citrate) approval history, Drugs@FDA: Clomiphene citrate (Clomid) was FDA-approved in 1967 for female ovulation induction, not for male use
8. U.S. Food and Drug Administration, 'Compounded Drugs' consumer information page: FDA states compounded drugs are not FDA-approved and are not verified by FDA for safety, effectiveness, or quality before being marketed